Acurx Pharmaceuticals’ (ACXP) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Acurx Pharmaceuticals (NASDAQ:ACXP) in a research note issued to investors on Thursday morning,Benzinga reports. They currently have a $12.00 price target on the stock.

Acurx Pharmaceuticals Stock Down 2.8 %

Shares of Acurx Pharmaceuticals stock opened at $1.72 on Thursday. Acurx Pharmaceuticals has a 12 month low of $1.52 and a 12 month high of $5.28. The stock has a market cap of $27.94 million, a PE ratio of -1.58 and a beta of -1.73. The business has a fifty day simple moving average of $1.95 and a 200-day simple moving average of $2.14.

Acurx Pharmaceuticals (NASDAQ:ACXP) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.17) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.06. During the same period last year, the business earned ($0.24) EPS. Analysts expect that Acurx Pharmaceuticals will post -0.98 EPS for the current fiscal year.

Institutional Investors Weigh In On Acurx Pharmaceuticals

An institutional investor recently raised its position in Acurx Pharmaceuticals stock. Prospect Financial Services LLC lifted its stake in Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) by 6.1% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 295,075 shares of the company’s stock after acquiring an additional 16,975 shares during the quarter. Prospect Financial Services LLC owned approximately 1.86% of Acurx Pharmaceuticals worth $561,000 as of its most recent filing with the Securities and Exchange Commission. 11.53% of the stock is owned by hedge funds and other institutional investors.

About Acurx Pharmaceuticals

Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.